Literature DB >> 16774660

Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia.

H-L Wang1, G-H Wang, Q-Y Li, C Shu, M-S Jiang, Y Guo.   

Abstract

OBJECTIVE: To compare the prevalence of Toxoplasma infection between the first-episode schizophrenia and the controls and to compare the clinical features between the Toxoplasma-seronegative and Toxoplasma-seropositive patients with schizophrenia.
METHOD: The rate of serum reactivity to Toxoplasma in 600 schizophrenia, 600 affective disorders, and 400 controls was investigated. The clinical symptoms of the schizophrenia patients were scored and compared.
RESULTS: The rate of IgG antibody, not IgM in the schizophrenia patients, was higher than the control groups, and the odds ratio of schizophrenia associated with IgG antibody was 2.22-5.12. The affective disorders did not differ in the rate of IgG or IgM antibody from the normal or the physical disease control. The seropositive schizophrenia patients had higher scores on the positive subscale and three components of Positive and Negative Symptoms Scale than the seronegative patients.
CONCLUSION: This study lent further weight to the hypothesis that exposure to Toxoplasma may be a risk factor for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16774660     DOI: 10.1111/j.1600-0447.2006.00780.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  34 in total

1.  The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey.

Authors:  Brad D Pearce; Deanna Kruszon-Moran; Jeffrey L Jones
Journal:  Biol Psychiatry       Date:  2012-02-10       Impact factor: 13.382

Review 2.  Interferon-gamma- and perforin-mediated immune responses for resistance against Toxoplasma gondii in the brain.

Authors:  Yasuhiro Suzuki; Qila Sa; Marie Gehman; Eri Ochiai
Journal:  Expert Rev Mol Med       Date:  2011-10-04       Impact factor: 5.600

3.  Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis.

Authors:  E Fuller Torrey; John J Bartko; Zhao-Rong Lun; Robert H Yolken
Journal:  Schizophr Bull       Date:  2006-11-03       Impact factor: 9.306

Review 4.  Effects of Toxoplasma gondii infection on the brain.

Authors:  Vern B Carruthers; Yasuhiro Suzuki
Journal:  Schizophr Bull       Date:  2007-02-23       Impact factor: 9.306

5.  Antibodies to cytomegalovirus and Herpes Simplex Virus 1 associated with cognitive function in schizophrenia.

Authors:  Brian H Shirts; Konasale M Prasad; Michael F Pogue-Geile; Faith Dickerson; Robert H Yolken; Vishwajit L Nimgaonkar
Journal:  Schizophr Res       Date:  2008-09-17       Impact factor: 4.939

Review 6.  Toxoplasma gondii and schizophrenia: a review of published RCTs.

Authors:  Sam D Chorlton
Journal:  Parasitol Res       Date:  2017-05-15       Impact factor: 2.289

7.  Shared Immune and Repair Markers During Experimental Toxoplasma Chronic Brain Infection and Schizophrenia.

Authors:  Jakub Tomasik; Tracey L Schultz; Wolfgang Kluge; Robert H Yolken; Sabine Bahn; Vern B Carruthers
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

8.  Fetomaternal and Pediatric Toxoplasmosis.

Authors:  Helieh S Oz
Journal:  J Pediatr Infect Dis       Date:  2017-12       Impact factor: 0.293

9.  AAH2 gene is not required for dopamine-dependent neurochemical and behavioral abnormalities produced by Toxoplasma infection in mouse.

Authors:  Ross McFarland; Zi Teng Wang; Yan Jouroukhin; Ye Li; Olga Mychko; Isabelle Coppens; Jianchun Xiao; Lorraine Jones-Brando; Robert H Yolken; L David Sibley; Mikhail V Pletnikov
Journal:  Behav Brain Res       Date:  2018-03-16       Impact factor: 3.332

10.  Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate.

Authors:  Guillaume Fond; Alexandra Macgregor; Ryad Tamouza; Nora Hamdani; Alexandre Meary; Marion Leboyer; Jean-Francois Dubremetz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-06-15       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.